Alumis Inc.
$24.71
▲
2.82%
2026-04-21 05:14:01
www.alumis.com
NMS: ALMS
Explore Alumis Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$3.18 B
Current Price
$24.71
52W High / Low
$30.6 / $2.76
Stock P/E
—
Book Value
$2.88
Dividend Yield
—
ROCE
-134.01%
ROE
-86.68%
Face Value
—
EPS
$-2.86
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
221
Beta
—
Debt / Equity
12.25
Current Ratio
4.34
Quick Ratio
4.34
Forward P/E
-7.13
Price / Sales
121.91
Enterprise Value
$2.66 B
EV / EBITDA
-6.07
EV / Revenue
110.62
Rating
Strong Buy
Target Price
$38.4
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Orchestra BioMed Holdings, Inc. | $4.35 | — | $268.03 M | — | -52.8% | -1.09% | $5.42 / $2.2 | $0.94 |
| 2. | Tarsus Pharmaceuticals, Inc. | $65.97 | — | $2.86 B | — | -16.64% | -23.39% | $85.25 / $38.51 | $8.07 |
| 3. | Onconetix, Inc. | $0.73 | — | $0.51 M | — | -40.18% | -1.15% | $74.3 / $0.67 | $50.53 |
| 4. | Aptorum Group Limited | $0.9 | — | $7.21 M | — | -12.89% | -10.79% | $4.47 / $0.65 | $2.84 |
| 5. | AtaiBeckley Inc. | $4.9 | — | $1.47 B | — | -76% | -3.9% | $6.75 / $1.29 | $0.61 |
| 6. | BiomX Inc. | $1.46 | — | $9.55 M | — | -101.67% | -3.17% | $14.71 / $1.5 | $-12.5 |
| 7. | BioMarin Pharmaceutical Inc. | $54.33 | 30.1 | $10.47 B | — | 5.99% | 5.94% | $66.28 / $50.76 | $31.65 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 1.93 M | 2.07 M | 2.67 M | 17.39 M | 0 M | — |
| Operating Profit | -96.44 M | -115.29 M | -140.54 M | -101.53 M | -98.62 M | — |
| Net Profit | -92.93 M | -110.75 M | 59.32 M | -98.96 M | -94.76 M | — |
| EPS in Rs | -0.75 | -0.9 | 0.48 | -0.8 | -0.77 | -1.73 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 24.05 M | 0 M | 0 M | 0 M |
| Operating Profit | -453.8 M | -300.75 M | -158.17 M | -113.85 M |
| Net Profit | -243.32 M | -294.23 M | -154.99 M | -111.93 M |
| EPS in Rs | -1.98 | -2.39 | -1.26 | -0.91 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 411.94 M | 340.99 M | 89.61 M | 108.17 M |
| Total Liabilities | 110.64 M | 80.89 M | 428.87 M | 303.41 M |
| Equity | 301.3 M | 260.1 M | -339.26 M | -195.24 M |
| Current Assets | 318.23 M | 306.19 M | 53.36 M | 102.56 M |
| Current Liabilities | 73.32 M | 50.91 M | 20.87 M | 13.35 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -369.52 M | -255.08 M | -129.97 M | -107.72 M |
| Investing CF | 287.88 M | -113.79 M | 60.47 M | -68.75 M |
| Financing CF | 2.07 M | 492.37 M | 89.68 M | 101.63 M |
| Free CF | -370.18 M | -256.81 M | -134.47 M | -110.13 M |
| Capex | -0.65 M | -1.73 M | -4.5 M | -2.41 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | 17.3% | -89.84% | -38.47% | — |
| Profit Margin % | -1011.75% | — | — | — |
| Operating Margin % | -1886.92% | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -1872.38% | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.